Fexuprazan Market

The Fexuprazan market is witnessing a CAGR of 4.5% during the forecast period of 2025-2035. Fexuprazan is a new potassium-competitive acid blocker (P-CAB) that is a valuable advancement in the management of acid-related gastrointestinal diseases, such as gastroesophageal reflux disease (GERD), erosive esophagitis, and Helicobacter pylori infection. Fexuprazan, which was developed by Daewoong Pharmaceutical, has a quick onset of action and sustained acid suppression, unlike conventional proton pump inhibitors (PPIs). Its mechanism of action is reversible inhibition of the H+/K+ ATPase enzyme, which results in effective and prolonged gastric acid suppression

Since its South Korean approval in July 2022, Fexuprazan has exhibited high clinical efficacy and safety. Clinical trials have revealed that Fexuprazan is both effective as an initial therapy and as a maintenance therapy in patients with GERD, with on-demand therapy as a preferred maintenance treatment by about 68% of patients. These results highlight its utility as a patient-friendly treatment option.

Daewoong Pharmaceutical has been proactive in expanding Fexuprazan’s global footprint. As of July 2024, the drug has entered or is poised to enter markets in 30 countries, including the Philippines, Mexico, Chile, and Ecuador. Regulatory applications have been submitted in 11 additional countries, such as China, Brazil, and Saudi Arabia, with export contracts secured in 14 more nations, including India and the UAE. This strategic move demonstrates Daewoong’s dedication to the mitigation of acid-related diseases as a global health burden.

In the Indian pharmaceutical sector, Sun Pharmaceutical Industries Ltd. has been approved by the Central Drug Standard Control Organisation (CDSCO) to produce and sell Fexuprazan Hydrochloride Tablets 40 mg used to treat erosive esophagitis. The approval marks the drug’s increasing popularity and potential in various healthcare practices.